DSM B.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
03 may 2012 - 07:24
Statutory name
DSM B.V.
Title
DSM agrees to acquire Kensey Nash to strengthen its biomedical business
Comments
- DSM (NYSE Euronext: DSM KON) to offer USD 38.50 for each share of Kensey Nash (NASDAQ: KNSY) in an all-cash transaction through a tender offer
- Total enterprise value of approximately USD 360 million (about €275 million)
- Kensey Nash existing guidance for its fiscal year ending June 2013: Net sales USD 100 million; EBITDA USD 36 million.
- Offer price represents 33% premium to Kensey Nash's closing share price on May 2, 2012
- Kensey Nash Board of Directors unanimously recommends the offer
- Kensey Nash is a leader in regenerative medicine and biomaterials R&D, with world class manufacturing and strong strategic partnerships
- Strong strategic fit; acquisition will strengthen and complement DSM Biomedical's business and capabilities
- Acquisition will put DSM Biomedical on the map as a new profitable growth platform for DSM
- Acquisition EPS accretive from 2013 onwards
Related downloads
Date last update: 20 December 2025